Cencora, Inc. (COR)

Over the past six months, Cencora's stock has experienced various events and analyst activities. As of April 6, 2026, the share price was $320.96, representing a 16.90% increase over the past year. In March 2026, Cencora announced an agreement to acquire EyeSouth Partners' retina business for $1.1 billion. While Evercore ISI lowered Cencora's price target, other firms boosted their price objectives and reiterated positive ratings in February 2026. Cencora reported robust first-quarter fiscal year 2025 results, with 13% revenue growth and 14% adjusted diluted EPS growth year-over-year, leading to a significant upward revision to its full-year guidance. Despite a recent price retreat, analysts reaffirmed a "buy" rating for Cencora in April 2026, citing strong fundamentals, consistent dividend growth, and a low payout ratio. Cencora also beat EPS expectations but slightly missed revenue estimates in its quarterly earnings reported on February 4th.

Cencora manages and adapts to demand seasonality through supply chain planning and scalable order fulfillment services. The company uses real-time visibility to make decisions and reduce overproduction risk. Its "Seasonal Vaccines Program" ensures the timely delivery of flu, COVID-19, and RSV vaccines, highlighting a specific seasonal aspect of its distribution business.

Cencora, Inc., formerly AmerisourceBergen, is an American drug wholesale and distribution company and contract research organization formed in 2001. Rebranded in 2023, it reflects a growing global presence and role in pharmaceutical access and care, operating in the hospital and healthcare sector. Cencora distributes pharmaceuticals, healthcare products, and home healthcare supplies, while also providing pharmacy services, global commercialization services, and consulting. The company offers specialty distribution through World Courier and contract research organization services.

Cencora has a significant global presence, operating in over 50 countries and across 1,300 locations worldwide, including North America, Europe, and select international markets. It has 26 pharmaceutical distribution centers in the United States and nine in Canada. The company is expanding its global third-party logistics (3PL) services and cold chain capabilities, with plans to open new facilities in Italy in 2026 and Texas in 2028.

Cencora's brand reputation has been shaped by its role in the healthcare supply chain, industry consolidation, and regulatory scrutiny. The renaming to Cencora in August 2023 aligned with its global footprint and role in pharmaceutical access and care. Cencora is recognized for creating positive "Humankind Value," particularly through contributions to Healthcare R&D, Pharmaceuticals, and Medical Services. Areas for improvement include Workplace Injuries and Greenhouse Gases. The company's commitment to supporting biopharma customers globally also contributes to its reputation.

Cencora's shareholder base is primarily led by large institutional investors, with 1479 institutional owners and shareholders holding a total of 179,515,236 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Walgreens Boots Alliance also holds a significant stake, though they recently reduced their position. Institutional investors collectively own approximately 97.5% of the company. Recent insider activity includes several officers selling shares.